Androgen deficiency in the aging male: benefits and risks of androgen supplementation (Q35207774)

7 August 2017

1 reference

title

Androgen deficiency in the aging male: benefits and risks of androgen supplementation (English)

1 reference

7 August 2017

1 reference

Louis Gooren

1 reference

7 August 2017

publication date

1 June 2003

1 reference

The Journal of Steroid Biochemistry and Molecular Biology

7 August 2017

published in

1 reference

7 August 2017

1 reference

7 August 2017

issue

2-5

1 reference

7 August 2017

page(s)

349-355

1 reference

Declining gonadal function in elderly men.

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Age, Disease, and Changing Sex Hormone Levels in Middle-Aged Men: Results of the Massachusetts Male Aging Study*

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

1 reference

7 January 2021

Global public health and the information superhighway. Doctors and students need computer training

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50- to 80-year-old men and women.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Osteopenia in Men with a History of Delayed Puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Oestrogen deficiency in men: where are we today?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Relations of endogenous anabolic hormones and physical activity to bone mineral density and lean body mass in elderly men

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Predictors of skeletal muscle mass in elderly men and women.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Testosterone influences spatial cognition in older men.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Endogenous sex hormones and cognitive function in older men.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Testosterone and depression in aging men

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Low serum testosterone and myocardial infarction in geriatric male inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Androgens and cardiovascular disease in men and women

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Regional obesity and risk of cardiovascular disease; the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Relation of components of insulin resistance syndrome to coronary disease risk

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Regional obesity and NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Androgens and abdominal obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Androgens and Erythropoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airways pressure therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Reversible reproductive dysfunction in men with obstructive sleep apnoea

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Obstructive sleep apnea syndrome induced by testosterone administration

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Influence of testosterone on breathing during sleep

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Androgen blockade does not affect sleep-disordered breathing or chemosensitivity in men with obstructive sleep apnea

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. 1992.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Serum steroids in normal males and patients with prostatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

From estrogen to androgen receptor: a new pathway for sex hormones in prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Effects of estrogen deprivation on human benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Endocrine patterns in patients with benign and malignant prostatic diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Prostate cancer: how much do we know and how do we know it?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Longitudinal evaluation of serum androgen levels in men with and without prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Volume change of the prostate and seminal vesicles in male hypogonadism after androgen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Prostate-specific antigen and prostate gland size in men receiving exogenous testosterone for male contraception

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Effect of long‐term oral testosterone undecanoate treatment on prostate volume and serum prostate‐specific antigen concentration in eugonadal middle‐aged men

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

7 alpha-methyl-nortestosterone (MENT): the optimal androgen for male contraception

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

Andropause, androgen therapy and prostate safety

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900206-1

7 January 2021

10.1016/S0960-0760(03)00206-1

Identifiers

DOI

1 reference

7 August 2017

1 reference